0000899243-20-021560.txt : 20200805 0000899243-20-021560.hdr.sgml : 20200805 20200805190100 ACCESSION NUMBER: 0000899243-20-021560 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200803 FILED AS OF DATE: 20200805 DATE AS OF CHANGE: 20200805 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weissman James B CENTRAL INDEX KEY: 0001598480 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 201079177 MAIL ADDRESS: STREET 1: C/O DICERNA PHARMACEUTICALS, INC. STREET 2: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205993609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-03 0 0001399529 Dicerna Pharmaceuticals Inc DRNA 0001598480 Weissman James B C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 EVP & Chief Operating Officer Common Stock 2020-08-03 4 M 0 4101 2.97 A 25961 D Common Stock 2020-08-03 4 M 0 259 3.42 A 26220 D Common Stock 2020-08-03 4 S 0 2928 22.312 D 23292 D Common Stock 2020-08-03 4 S 0 1432 22.7993 D 21860 D Employee Stock Option (Right to Buy) 2.97 2020-08-03 4 M 0 4101 0.00 D 2027-01-03 Common Stock 4101 21879 D Employee Stock Option (Right to Buy) 3.42 2020-08-03 4 M 0 259 0.00 D 2023-09-24 Common Stock 259 17440 D The Reporting Person sold an aggregate of 4,360 shares of common stock on August 3, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 0.58% of 757,238 shares of common stock, which is the number of shares of common stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 25, 2019. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.75 to $22.74, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.76 to $22.86, inclusive. The Reporting Person undertakes to provide to Dicerna Pharmaceuticals, Inc., any security holder of Dicerna Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. The option vests in 48 monthly installments over the four-year period starting on the last day of January 2017, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date. The vesting of this option was subject to achievement of pre-established performance goals. As of the transaction date, the options were fully vested. /s/ Douglas W. Pagan, attorney-in-fact 2020-08-05